| Literature DB >> 26500105 |
Yong Zhang1, Zhen Shao2, Xiuying Zhang2, Xiao Jia2, Yan Xia2, Yanyan Zhang2, Ning Xin3, Mingfeng Guo4, Jing Chen2, ShuangShuang Zheng2, YuZhong Wang5, Linlin Fu6, Ruiguo Dong2, Chenghua Xiao2, Deqin Geng2, Yonghai Liu7.
Abstract
Th17-related cytokines have been suggested to play a crucial role in myasthenia gravis (MG) pathogenesis.The tumor necrosis factor (TNF)-α-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), is a newly identified member of the tumor necrosis TNFAIP8 family which is an essential negative regulator of both innate and adaptive immunity. In the present study, the expression of TIPE2 mRNA and protein in peripheral blood mononuclear cells (PBMC) from healthy and MG subjects were detected by Real-time PCR and Western blotting.The serum IL-6, IL-17 and IL-21 levels were tested by ELISA. Furthermore, PBMC from MG patients were purified and stimulated with LPS (TLR4 agonist) with or without transfection of TIPE2 expressing adenovirus, then the expression of TIPE2 and Th17-specific transcriptional factor RORγt and the IL-6, IL-17 and IL-21 levels of supernatant were analized. Our data demonstrated that the expression of TIPE2 mRNA and protein was reduced in MG compared with normal controls, with lower expression in generalized patients than in ocular ones. Furthermore, TIPE2 mRNA presents a significantly negative correlation with the serum levels of IL-6, IL-17 and IL-21 in either generalized patients or ocular patients. In cultured MG PBMC, TLR4 activation led to the down-regulation of TIPE2, while the expression of RORγt and production of IL-6, IL-17 and IL-21 were significantly increased. However, when TIPE2 was overexpressed, these TLR4 activation-induced effects were significantly abrogated. Overall, our results indicated for the first time that TIPE2 may participate in the development of MG through negatively regulation of TLR4-mediated autoimmune T helper 17 cell responses.Entities:
Keywords: Myasthenia gravis; TIPE2; TLR4; Th17-related cytokines
Mesh:
Substances:
Year: 2015 PMID: 26500105 DOI: 10.1007/s11481-015-9638-5
Source DB: PubMed Journal: J Neuroimmune Pharmacol ISSN: 1557-1890 Impact factor: 4.147